Q2 Earnings Estimate for ARWR Issued By HC Wainwright

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Wednesday, February 12th. HC Wainwright analyst P. Trucchio anticipates that the biotechnology company will earn $2.66 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2025 earnings at $1.53 EPS, FY2026 earnings at ($4.21) EPS, FY2027 earnings at ($3.27) EPS, FY2028 earnings at ($3.20) EPS and FY2029 earnings at ($1.29) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.97).

ARWR has been the subject of a number of other reports. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Citigroup reduced their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. Chardan Capital reiterated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Sanford C. Bernstein reduced their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. Finally, Piper Sandler lowered their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Stock Up 4.4 %

ARWR stock opened at $19.95 on Monday. The stock has a 50-day simple moving average of $20.00 and a two-hundred day simple moving average of $21.05. Arrowhead Pharmaceuticals has a twelve month low of $17.05 and a twelve month high of $36.72. The firm has a market capitalization of $2.50 billion, a PE ratio of -3.97 and a beta of 0.95. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently bought and sold shares of ARWR. R Squared Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $38,000. Values First Advisors Inc. purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $52,000. Van ECK Associates Corp boosted its position in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 788 shares during the last quarter. Finally, KBC Group NV increased its position in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 1,644 shares during the period. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the transaction, the insider now directly owns 272,122 shares of the company’s stock, valued at approximately $5,393,458.04. This trade represents a 10.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the business’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. Following the completion of the sale, the director now directly owns 36,740 shares of the company’s stock, valued at approximately $734,800. This trade represents a 7.20 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 147,432 shares of company stock worth $2,957,986. 4.30% of the stock is currently owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.